Karolinska Development AB
Fogdevreten 2, Solna
Stockholm
S-171 77
Tel: 46-0-8-524-865-91
153 articles about Karolinska Development AB
-
Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
7/9/2019
Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction.
-
Karolinska Development publishes its Annual Report for 2018 with an update on the financial situation
4/30/2019
Karolinska Development AB has published its Annual Report for 2018.
-
Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting
4/26/2019
Karolinska Development AB announces that The Board of Directors has decided to delay the publication of its Annual Report for 2018.
-
Karolinska Development's portfolio company Dilafor secures financing for continued development of tafoxiparin
4/23/2019
Karolinska Development AB announces that its portfolio company Dilafor AB has completed a capital raising and is planning to start a new Phase 2b study of tafoxiparin to soften the cervix prior to labor induction.
-
Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-246
4/16/2019
Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes having a TP53 mutation.
-
Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents
4/3/2019
Karolinska Development's portfolio company Aprea presents results from studies with APR-246 in combination with immune checkpoint blockade.
-
Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer
3/25/2019
Karolinska Development's portfolio company Aprea Therapeutics announces that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO).
-
Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical
3/15/2019
Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite Surface Technologies in Limb Salvage Surgery.
-
New US investor joins Series C financing of Karolinska Development's portfolio company Aprea Therapeutics
2/27/2019
Karolinska Development's portfolio company Aprea Therapeutics announces that funds managed by Janus Henderson Investors has joined its Series C financing as a new investor, raising the total amount of the financing from EUR 50 to EUR 55 million.
-
Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin
2/22/2019
Karolinska Development's portfolio company Modus Therapeutics announces that the first cohort has been successfully dosed in its
-
Karolinska Development: Q4 and 2018 Year-End Report - January-December
2/14/2019
Karolinska Development AB publishes its Q4 and 2018 Year-End Report with a positive quarterly and full-year result. The full report is available on the Company's website.
-
Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North
2/12/2019
Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million.
-
Karolinska Development's portfolio company Umecrine Cognition presents phase 2a results for GR3027 in idiopathic hypersomnia
1/29/2019
Karolinska Development's portfolio company Umecrine Cognition announces overall results from a phase 2a study with the candidate drug GR3027 in patients with idiopathic hypersomnia.
-
Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin
1/7/2019
Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD).
-
Financing of SEK 512 million secured in Karolinska Development's portfolio company Aprea Therapeutics
11/30/2018
Karolinska Development announces that an investment consortium, including Redmile Group, invests SEK 512 million (EUR 50 million) in Aprea Therapeutics.
-
Karolinska Development's portfolio company Dilafor presents top line results from a Phase 2b study with tafoxiparin
10/31/2018
Karolinska Development announces today top line results from a Phase 2b study with tafoxiparin in treatment of protracted labor. The results show that the study did not achieve its primary endpoint of reducing the time to vaginal delivery through treatment with tafoxiparin. Karolinska Development will revalue the portfolio company's book value, which is expected to negatively impact the result by SEK 40 million for the fourth quarter of 2018.
-
Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug
10/22/2018
Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market.
-
Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North
9/24/2018
Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.
-
BioArctic, a Company in Karolinska Development's Portfolio, Announces That the Phase IIb Study of BAN2401 in Early Alzheimer's Disease Continues Toward 18-Month Endpoint
12/21/2017
Karolinska Development announces today that BioArctic's drug candidate BAN2401 did not meet the criteria for success at a 12-month interim analysis of a Phase IIb study in patients with early Alzheimer's Disease.
-
Karolinska Development's Portfolio Company Modus Therapeutics Announces Publication of Phase I/II Data Demonstrating Anti-Adhesive Properties of Sevuparin
12/20/2017
Karolinska Development announced today that data from a Phase I/II study of sevuparin in malaria patients was published in an on-line version of the renowned scientific journal PLOS ONE.